


# Accepted Manuscript

Safety and pharmacokinetics of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) in healthy adult subjects of Japanese descent

Paul Dorinsky, Paolo DePetrillo, Shahid Siddiqui, Andrea Maes, Colin Reisner



PII: S1094-5539(18)30034-8

DOI: [10.1016/j.pupt.2018.05.001](https://doi.org/10.1016/j.pupt.2018.05.001)

Reference: YPUPT 1729

To appear in: *Pulmonary Pharmacology & Therapeutics*

Received Date: 5 February 2018

Revised Date: 20 April 2018

Accepted Date: 11 May 2018

Please cite this article as: Dorinsky P, DePetrillo P, Siddiqui S, Maes A, Reisner C, Safety and pharmacokinetics of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) in healthy adult subjects of Japanese descent, *Pulmonary Pharmacology & Therapeutics* (2018), doi: 10.1016/j.pupt.2018.05.001.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Safety and Pharmacokinetics of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhaler (BGF MDI) in Healthy Adult Subjects of Japanese Descent**

Paul Dorinsky<sup>a,\*</sup>, Paolo DePetrillo<sup>b</sup>, Shahid Siddiqui<sup>c</sup>, Andrea Maes<sup>d</sup>, Colin Reisner<sup>c,d</sup>

<sup>a</sup>*Pearl – A member of the AstraZeneca Group, Durham, NC, USA;* <sup>b</sup>*Pharmaron, Baltimore, MD, USA;* <sup>c</sup>*AstraZeneca, Gaithersburg, MD, USA;* <sup>d</sup>*Pearl – A member of the AstraZeneca Group, Morristown, NJ, USA*

\*Corresponding author. Pearl – A member of the AstraZeneca Group, 4222 Emperor Blvd, Suite 560. Durham, NC 27703, USA. Tel: +1 919 809 7449. *E-mail address:* paul.dorinsky1@astrazeneca.com (P. Dorinsky).

Dr Paolo DePetrillo, Pharmaron, 800 West Baltimore Street, Baltimore, MD 21201, USA.  
Email: paolo.depitrillo@pharmaron-us.com

Dr Shahid Siddiqui, AstraZeneca, One MedImmune Way, Gaithersburg, MD 20878, USA.  
Email: shahid.siddiqui@astrazeneca.com

Dr Andrea Maes, Pearl – A member of the AstraZeneca Group, 280 Headquarters Plaza, East Tower, 2nd Floor, Morristown, NJ 07960, USA. Email: andrea.maes@astrazeneca.com

Dr Colin Reisner, Pearl – A member of the AstraZeneca Group, 280 Headquarters Plaza, East Tower, 2nd Floor, Morristown, NJ 07960, USA. Email: colin.reisner@astrazeneca.com

Manuscript word count (without tables and figures): 3691

Abstract word count: 289

Download English Version:

<https://daneshyari.com/en/article/8537694>

Download Persian Version:

<https://daneshyari.com/article/8537694>

[Daneshyari.com](https://daneshyari.com)